TVM Capital Life Science
VC Fund
Munich, Germany
TVM Capital Life Science is a dedicated life science venture capital firm, with offices in Montreal, Canada and Munich, Germany. Since inception, TVM Capital Life Science has invested in entrepreneurial venture backed companies. Over several fund generations, their investment strategy has included a multi-stage investment approach spanningdiscovery to market ready companies as well as profitable companies searching for growth capital. Their investment focus has always been broad and includes investments in therapeutics, technology platforms, medtech and diagnostics. They invest in Canada, the U.S., Germany and Western Europe with their dedicated team of investment professionals based in Montreal and Munich.
- Total investments:
- 33
- Last investment:
- Lead investor:
- 67%
- Fund size:
- $478M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries TVM Capital Life Science invests in
Stages TVM Capital Life Science invests in
Countries TVM Capital Life Science invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $8.6M–$28M
- Series C
- $11M–$37M
- Venture - Series Unknown
- $12M–$24M
Investment Focus
Industry
- Health Care 12 (36%)
- Biotechnology 8 (24%)
- Medical Device 8 (24%)
- Medical 7 (21%)
- Pharmaceutical 5 (15%)
Stage
- Venture - Series Unknown 8 (24%)
- Series A 4 (12%)
- Series C 3 (9%)
- Series B 2 (6%)
- Series D 2 (6%)
Country
- United States 7 (21%)
- Canada 5 (15%)
- Germany 4 (12%)
- Switzerland 1 (3%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Catello Somma
Associate
|
Associate | Total investments: 1 | Find email | |
Hubert Birner
Managing Partner
|
Managing Partner | Total investments: 8 | Find email | |
Luc Marengere
Managing Partner
|
Managing Partner | Total investments: 11 | Find email | |
Marc Riviere
General Partner
|
General Partner | Total investments: 0 | Find email | |
Sascha Berger
Partner
|
Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Egg Medical is a medical device company that offers EGGNEST, a passive protection designed to drastically reduce scatter radiation exposure for the entire cath lab team without disruption to workflow. It is an in integrated work platform built on a carbon fiber sled base designed to drastically reduce scatter radiation exposure without disruptingworkflow. | $14.3M / Mar 01, 2025 | ||
| CSA Medical provides cryotherapy systems. It offers CryoSpray Ablation system, which enables the physicians to freeze, destroy, and remove unwanted tissues, as well as transports liquid nitrogen that is passed through a standard endoscope. CSA Medical was formerly known as Crymed Technologies and changed its name to CSA Medical in April 2006.Thecompany was incorporated in 1993 and is based in Lutherville Timonium, Maryland. | $53M / Series D / Sep 09, 2024 | ||
| leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. | Series D / Aug 06, 2024 | ||
| Smart Reporting offers a digital health solution for structured medical reporting. Smart Reporting offers an intelligent software for physicians which improves quality and efficiency. The first platform was launched in radiology and supports radiologists in generating high-quality medical reports by applying guideline-compliant criteria in theirreports. | $24.5M / Series C / Apr 22, 2024 | ||
| Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. | $25M / Series A / Feb 05, 2024 | ||
| Myo is a communication platform for the care market.they are proud to have designed a product with Myo that brings together people in care.their team is always looking for new talents who would like to work on a product for better care. | $8.6M / Series A / Jan 31, 2024 | ||
Recurv Pharma
|
Recurv Pharma's RP-001 is a novel chemical entity (NCE) that is administered in a nano-emulsion formulation, concentrating medication delivery to the tumour while preserving healthy organs. Strong efficacy in a variety of pre-clinical tumour models, including non-small cell lung, breast, ovarian, prostate, pancreatic, and colorectal cancers,has allowed the chemical to show that it can destroy tumours even in multi-drug resistant tumours. | $24M / Venture - Series Unknown / Feb 01, 2023 | |
| Egg Medical is a medical device company that offers EGGNEST, a passive protection designed to drastically reduce scatter radiation exposure for the entire cath lab team without disruption to workflow. It is an in integrated work platform built on a carbon fiber sled base designed to drastically reduce scatter radiation exposure without disruptingworkflow. | $13M / Venture - Series Unknown / Feb 26, 2022 | ||
| CENTOGENE is one of the largest genetic biotech companies worldwide, the European market leader, and one of the global leaders in genetic diagnostic analyses of rare inherited diseases. Transforming global genetic data into medical decisions, that are focused on creating broarder awareness for patients of all ethnicities around the world. CENTOGENEis a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for Patients. With headquarters in Rostock, Germany and further operations in Berlin, Germany as well as Cambridge, Massachusetts, USA, CENTOGENE is dedicated to transforming the science of genetic information into solutions and hope for patients with rare diseases and their families. CENTOGENE provides the full spectrum of modern methods and technology for human genetics analysis; it is active in research and is constantly developing new and innovative products for human genetics. | $16.9M / Post-IPO Equity / Feb 01, 2022 | ||
| Access Vascular has developed a disruptive technology using a novel material process intended to significantly reduce the blood component accumulation (thrombosis or blood clotting) that leads to occlusions and infections. Over the last three years, Access Vascular’s technology has demonstrated the potential for superior clinical outcomes and lowerhealthcare costs compared with existing technologies. For patients, their solutions are predicted to decrease morbidity, shorten hospital stays, advance treatment, and minimize pain.Their technology has the potential to address a range of clinical needs in a variety of indications. Access Vascular is focused initially on launching their HydroPICC, a peripherally inserted central catheter with superior material performance over the current lagging technology. | $20M / Series B / Mar 03, 2021 | ||
| See all 33 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does TVM Capital Life Science invest in?
TVM Capital Life Science invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Venture - Series Unknown and Series A stage. Most of the 33 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is TVM Capital Life Science's check size?
TVM Capital Life Science typically joins rounds of $8.6M–$28M at Series A, $11M–$37M at Series C and $12M–$24M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds TVM Capital Life Science participates in.
How do I contact TVM Capital Life Science?
Public channels for TVM Capital Life Science include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at TVM Capital Life Science?
The team at TVM Capital Life Science includes Catello Somma (Associate), Hubert Birner (Managing Partner) and Luc Marengere (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
